Our findings suggest that the KEAP1/NFE2L2 mutations may be a poor prognostic biomarker for NSCLC, and compared with docetaxel, atezolizumab did not prolong OS in patients with KEAP1/NFE2L2 mutations. Here, NFE2L2 is linked to non-small cell lung carcinoma.